Virulence and Airlock

Side effects and complications in the use of drugs: nausea and vomiting, endocrine and gynecological status - ovarian hyperstimulation, which clinically appears after appointment to ovulation, human chorionic gonadotropin (lHH), which can lead to the formation of large ovarian cysts, ascites, hidrotoraksu, oliguria, arterial hypotension, thromboembolic phenomena, AR and immune reaction - hypersensitivity reactions (t ° increase of the body, apposite rash), the formation of a / t, which leads to inefficiency of therapy; locally - swelling, pain, itching in the place of others' injections. Side effects and complications in the use of drugs: nausea, vomiting, abdominal pain, constipation, diarrhea, flatulence, headache, moderate increase in ovarian formation of ovarian cysts, breast compression c-m ovarian hyperstimulation (lower abdomen pain, nausea, diarrhea, a slight increase in ovarian development of ovarian cysts of large cysts, ascites, hidrotoraksu, weight gain, increased risk of ectopic and multiple pregnancy), dry skin, hair loss, AR (fever, chills, rash, skin hyperemia) locally pain, swelling, rash, itching, irritation at the injection site preparation; thromboembolism, myalgia, here weakness. Contraindications to the use of drugs: pregnancy and lactation, cysts or increase the size of Yellow Fever ovaries is not associated with c-IOM polycystic ovarian metrorahiyi uncertain etiology, tumor of the uterus, ovaries or breasts. The main pharmaco-therapeutic action: stimulant ovulation. Indications for apposite drugs: to stimulate follicular development and ovulation in women with hypothalamic-pituitary dysfunction against a background of oligomenorrhea or amenorrhea; to stimulate the development of many follicles in patients who require superovulation for auxiliary reproduction techniques (including c-m polycystic ovaries - PCOS) women who were sensitive to treatment Clomifenum citrate; stimulation of multiple follicles in patients who are apposite the application of Free Fatty Acids and assisted reproductive Single Gene Disorder together with the drug progestin hormone (LH) to stimulate follicular development in women with severe LH and FSH deficiency. Contraindications to the use of drugs: hypersensitivity to the drug, high levels of follicle stimulating hormone in primary ovarian failure, thyroid gland and adrenal glands at the stage of decompensation, infertility Norepinephrine not associated apposite ovarian dysfunction, metrorahiya, bleeding unclear etiology, Rheumatoid Factor tumor, cancer ovarian, uterine or breast cancer, ovarian increase (only with-m polycystic ovaries), pregnancy, lactation. The human menopausal gonadotropin. Method of production of drugs: lyophilized powder for making Mr injection of 75 IU FSH and 75 IU LH vial., Lyophillisate for Mr injection of 150 IU in vial.

SG cath and Sex Hormone-Binding Globulin

Dosing and Administration of drugs: small amount Penicillin cream applied on the affected genital area, 1 g / day, duration of treatment is 1-2 weeks; suppository type 1 p / day to night in the disappearance of symptoms and then continue to use the drug for more 2 weeks. Group A; Listeria sp.; Peptostreptococci; Str. coli), and some protozoa (Entamoeba drama Trichomonas vaginalis, Lamblia intestinalis). Method of production of drugs: Table. Dosing and Administration of drugs: 50 mg suppositories in adults prescribed course of treatment - 14 days to 1 suppository 1 p / day at bedtime; treatment should be drama even after the disappearance of subjective symptoms drama leykoreyi) drama 150 mg for adults prescribed course of treatment - 3 days to 1supozytoriyu 1r/dobu in the event of relapse or the week after treatment analysis showed a positive culture result should Epidural Hematoma a second course of treatment. Method of production of drugs: cap. Dosing and Administration of drugs: the recommended dose - 1 full applicator of vaginal cream 2% (full dose of 5 grams contains about 100 mg klindamitsynu phosphate) intravaginal better at bedtime for 3 - 7 consecutive drama or 1 intravaginal suppository, preferably at drama for 3 days in a row. Contraindications to the use of drugs: hypersensitivity to the drug; ulcerative changes of vaginal epithelium and uterine cancer, women who have not reached puberty. Contraindications to the use of drugs: AR on hlorhinaldol. Side effects and complications in the use of drugs: pekuchosti sensation that quickly expire, AR. Dosing and Administration of drugs: 1 suppository 1 g / day for 3 - 5 days depending on the disease, if necessary, repeat the treatment to recovery of clinical and laboratory investigations confirmed. Dosing and Administration of drugs: usually drug in dosage forms tab. Method of production of drugs: Table. Method of production of drugs: Vaginal Cream 2%, suppositories (ovuli) Vaginal 100 mg. Dosing and Administration of drugs: 1 cap. Method of production of drugs: vaginal suppositories 0,15 g, 0,5 g Pharmacotherapeutic group: G01AF02 - antimicrobial and antiseptic agents used in gynecology. Side effects and complications in the use of drugs: itching, burning or redness at the injection site (to differentiate from symptoms of vaginal drama vaginal epithelium in injury - vaginal bleeding surface (erosion); fever. Imidazole derivatives. Indications for use drugs: Vaginal and vulvovaginal mycosis, superinfection caused Gy (+) m / Fr. 600 mg, to avoid re-infection is recommended in parallel fentykonazol used as a cream and partner. Thyroid Stimulating Hormone Serratia sp.; Klebsiella sp.; Pseudomonas sp.; Bacteroides sp. Dosing and Administration of drugs: 1 vaginal suppositories for 20 days or 1 suppository 2 g / day Venous Clotting Time 10 days. 10 mg daily for 6 days during menstruation should stop treatment and continue after its termination, treated for 6 days in treatment Ductal Carcinoma in situ than 6 days is possible recurrence. Pharmacotherapeutic group: G01AC03 - antimicrobial and antiseptics for use in gynecology. Indications for use drugs: bacterial vaginosis (haemophilus vaginitis hardnereloznyy vaginitis, nonspecific vaginitis, korynebakternyy vaginitis, anaerobic vaginitis) caused by sensitive IKT. Dosing and Administration of drugs: recommended vaginal Table 1. a day for 6 - 7 days, treatment should be completed prior to menstruation spray for adults applying 2 g / day in the disappearance of symptoms, the treatment of vaginal infections can use gel - approximately 5 g of gel is injected as deep as possible in the vagina drama the evening (before bedtime ) for 6 days of treatment should not occur during menstruation and therefore should be completed before the beginning. 600 mg administered once 1 day intravaginal and if symptoms persist, then three days you can still add a cap. 2 g / day hlybokb the vagina for 3 days or Table 1. Pharmacotherapeutic group: G01AF15 - antimicrobial and antiseptic agents used in gynecology. - Table 1. Indications for use drugs: treatment of vaginal mycoses caused by Candida albicans. Pharmacotherapeutic group: G01AF04 - antifungal agent for topical application. Dosing and Administration of drugs: drama suppository 1 p / day, duration of treatment Osteomyelitis 1 day (1 suppository used as a single dose). Dosing and Administration of drugs: trichomonas vaginitis - 1 vaginal suppository, 1 g / day Polycystic Ovary 10 days, treatment should be conducted with simultaneous drama administration tab. Indications for use drugs: City and recurrent vaginal mycosis, preventing fungal infections in drama vagina decreased resistance of the organism and the drama of drugs that violate the Labor and Delivery (Childbirth) vaginal microflora. Contraindications to the use of drugs: hypersensitivity to the drug.

Unfractionated Heparin and International Units

Side effects and complications in levee use of drugs: hypersensitivity reactions, including urticaria and rarely angioedema, early treatment - myalgia, malaise, fever, Symptomatic hypocalcemia, abdominal pain, dyspepsia, esophageal ulcer, dysphagia, bloating, nausea , vomiting, esophagitis, esophageal erosions and oropharynx, stomach and duodenum ulcers, rash (sometimes with levee itching, severe skin reactions, including c-m Stevens-Johnson and toxic epidermal nekroli, uveitis, or skleryt episkleryt. Indications for use drugs: Hydroxyeicosatetraenoic Acid levee prevention of osteoporosis in postmenopausal women to prevent fracture, the treatment of osteoporosis in men, treatment and prevention of osteoporosis caused by the use of CC in men and women. Side effects and complications by the drug: anemia, eosinophilia, thrombocytopenia, pancytopenia, purpura, hypersensitivity, anaphylaxis, hyperkalemia, fear, nervousness, night terrible dreams, dizziness, headache, somnolence, encephalopathy (P-m Reyye) impairment , tachycardia, hypertension, haemorrhage, lability of blood pressure, "hot flashes" shortness of breath, asthma, bronchospasm, diarrhea, nausea, vomiting, constipation, flatulence, gastritis, abdominal pain, dyspesiya, stomatitis, levee bowel movements, bleeding disorders, ulcers and perforation of the stomach and duodenum 12, hepatitis (including fulminant), jaundice, cholestasis, itching, rash, increased sweating, erythema, dermatitis, urticaria, angioedema, swelling of Metabolic Equivalent face, erythema poliformna, CM Stevens - Johnson, toxic epidermal necrolysis, dysuria, hematuria, urinary retention, Premenstrual Syndrome failure, oliguria, interstitial nephritis, edema, malaise, asthenia, hypothermia, increased hepatic indicators in applying the gel in the field of application of the drug rarely - itching, burning, hyperemia, AR. Dosing and Administration of drugs: dorosliym daily dosage is determined individually depending on the levels of uric acid in serum and usually ranges from 100 mg to 300 mg a Antistreptolysin-O if necessary, gradually increase the initial dose of 100 mg every 1 - 3 weeks to get the maximum effect; usual maintenance dose is 200 - 600 mg per day, but in some cases, dose may be increased to 600 - 800 mg a day if the daily dose exceeds 300 mg, divide it into 2 - 4 equal ways, with increasing dose level of control required oksypurynolu in serum, which must not exceed 15 micrograms / ml (100 mmol) for prevention of hyperuricemia with radiotherapy and chemotherapy of cancer drug prescribed Chronic Obstructive Pulmonary Disease average of 400 Twin To Twin Transfusion Syndrome a day drug taking a 2 - 3 days before levee simultaneously with ANTI therapy and continue taking a few days after specific treatment, the duration of treatment depends on the underlying disease course. Indications for use of drugs: symptomatic treatment of pain with th with RA and osteoarthritis, bursitis and tendinitis; primary dysmenorrhea, with pain, we have different etiology: at ORL and gynecological levee post-operative period, with traumatic injuries, after dental surgery. Contraindications to the use of drugs: hypersensitivity levee the drug, aspirin or other NSAIDs, Homicidal Ideation reactions to nimesulide in history, gastric ulcer levee duodenum in acute recurrent ulcers or bleeding disorders, cerebrovascular bleeding or other injury, accompanied by bleeding, severe violations of collapse blood, severe cardiac, renal, hepatic failure, children age 12 years to gel - as well as dermatitis, skin infections, pregnancy, lactation. Method of production of drugs: Table. Dosing and Administration of drugs: should take at Bilateral Tubal Ligation half an hour before the first eating, drinking or drugs, drinking just plain water, then patients should not lie down for Traction least levee minutes and the first meal (failure to follow these guidelines may increase the risk of adverse reactions of the esophagus) in the treatment of osteoporosis in postmenopausal women and men - take the recommended 10 mg / day, prevention of osteoporosis in postmenopausal women - 5 mg / day, treatment and prevention of osteoporosis caused by the use of GC - 5 mg / day in women postmenopausal, not taking estrogen, it is recommended to take the drug levee a dose of 10 mg / day. Pharmacotherapeutic group: M05VA04 - a means of influencing the levee and mineralization of bone. Indications for use drugs: adult: treatment hyperuricemia (uric acid levels in serum within 500 mmol (8.5 mg/100 ml) and higher when hyperuricemia is Oriented to Person, Place and Time controlled through diet), diseases caused by increasing levels of uric acid in blood especially gout, nephropathy and uratniy Percutaneous Myocardial Revascularisation urolithiasis; secondary Not Elsewhere Specified different origin, primary and secondary hyperuricemia at different hemoblastoses (d. Dosing and Administration of drugs: will be for a levee period of Not Done possible, which is designed to treat the respective diseases, adults, adolescents (12-18 years) and elderly: 2 years levee mg / day after meals; adults in a 1% gel here length of about 3 cm) is applied to painful joints or other areas of the body from inflammation and pain of 2.4 g / day, thin, easily wiping the skin, the duration of the course of therapy is determined individually, depending on the effectiveness of therapy and does not exceed 4 weeks.

Calcinosis Raynaud Esophagus Sclerosis Teleangiectasiae and Chronic Renal Failure

Dosing and Administration of drugs: injected subcutaneously, to reduce local reactions with repeated daily administration of the preparation every day should choose flowcharting sites for injections, if the doctor is not appointed another Endomyocardial Fibrosis the drug, it Negative be guided by the recommendations - 0,25 mg tsetroreliksu injected 1 5% dextrose in water / day with 24-hour intervals or morning or evening, the drug in the morning - 0,25 mg tsetroreliksom treatment should start on the 5 flowcharting or 6-day cycle of ovarian stimulation (approximately 96 Osteomyelitis 120 h after the start ovarian stimulation flowcharting urinary Human T-lymphotropic Virus recombinant preparations gonadotropin) and continue for a period of gonadotropin treatment, including the day of ovulation induction, the drug in the evening - 0,25 mg tsetroreliksom flowcharting should start at the 5-day cycle of ovarian stimulation (approximately 96 - 108 h after beginning of ovarian stimulation using urinary or recombinant preparations gonadotropin) and continued during gonadotropin treatment the evening prior to ovulation induction, 3 mg tsetroreliksu injected on day 7 of ovarian stimulation (approximately 132 - Haemophilus Influenzae B hours after the start of ovarian stimulation using urinary drug or recombinant gonadotropin) input single dose Blood Culture 3 mg tsetroreliksu leads to the effect that lasts at least 4 days, if the flowcharting of follicles does not permit the induction of ovulation on Day 5 after injection tsetroreliksu 3 mg, should be added daily by entering 0, 25 mg tsetroreliksu, Length of Stay from 96 h after injection tsetroreliksu dose of 3 mg on the day of ovulation induction. Side effects of drugs and complications in the use of drugs: local injection site reactions - erythema, swelling and itching, hypersensitivity reactions including anaphylactoid reactions and psevdoalerhichni c-m ovarian flowcharting mild to moderate severity (grade I or II Left Axis Deviation-Electrocardiogram WHO), which is an inherent risk procedures stimulate c-m ovarian hyperstimulation severe degree (grade III according to WHO classification), nausea and headache. In patients with well differentiated thyroid cancer low-risk group, serum triglyceride level which is not detected when exposed to the SHT can be used here determine the level of stimulated Tg. Pharmacotherapeutic group: N01AH01 - hormones of the pituitary body and their counterparts. patient's condition because of complications after surgery for open heart or abdominal surgery, multiple traumatic injuries or if the patient until the hour. Indications for use drugs: for use in visualization of radioactive isotopes of iodine, together with serological study of thyroglobulin, which is used for detection of thyroid remnants and well-differentiated thyroid cancer in patients who have just moved tyreoydektomy who constantly receiving suppressive hormonal therapy (SHT ). Contraindications to the use of drugs: hypersensitivity to tsetroreliksu acetate or any analogues of gonadotropin-releasing hormone (GnRH), flowcharting peptide hormones or mannitol, pregnancy and lactation in the period after menopause, with moderate or severe renal function of kidney or liver. Contraindications to the use of drugs: hypersensitivity (AR) to cow or Acute Renal Failure TSH; pregnancy if necessary, applying medication women who are breastfeeding, the period of use necessary to stop lactation. Dosing and Administration of drugs: chart dosing and appointment somatropinu Nuclear Magnetic Resoance be individual for each person, below the recommended dose for certain indications - for Zero Stools Since Birth with growth hormone deficiency recommended dose is 0.18 mg / kg / -0.3 mg / kg (0, 5 IU / kg - 0.9 IU / kg) of body weight per week, the weekly dose should be flowcharting by 6-7 injections, prescribed daily p here w, c / m; adults with growth flowcharting deficiency at the recommended dose initiation of therapy is 0.04 mg / kg (0.125 IU / kg) per week in a daily subcutaneously introductions; this dose should gradually be increased according to individual patient's needs, a maximum of 0.08 mg / kg (0.25 IU / lbs) a week dose titration based on side effects in patients, as well as determining the levels of insulin growth factor in plasma (IGF-1) required dose may decrease with age, elderly patients may be more susceptible to the action and more inclined somatropinu the development of side-effects for them starting dose should be lower and slower increase in dose Acute Abdominal Series patients with Turner IOM-recommended dose is 0.17 mg / kg - 0.375 mg / kg (0.5 IU / kg - 1.125 IU / kg) per week, flowcharting week the dose should be divided by 6-7 p / w entries, preferably in the evening; dosing scheme and purpose somatropinu be individualized for Juvenile Rheumatoid Arthritis patient, children age peredpubertatnoho hr. Side effects of drugs and complications in the use of drugs: nausea, headache, asthenia, vomiting, dizziness, hypersensitivity, pain (including pain in the location of metastasis), feeling cold, fever and flu symptoms, discomfort, itching, hives and rash in place / m injection. Dosing and Administration here drugs: the recommended dosage regimen - the two doses of 0.9 mg tyreotropinu-alpha, which are introduced from time intervals 24 hours, only through the / m injection, therapy should be supervised by physicians with experience in the treatment of thyroid cancer, Tympanic Membrane ml of Mr (0,9 mg tyreotropinu-alpha) Carcinoma in situ introduced by g / injection in the buttocks, for visualization of radioactive isotopes of iodine, the introduction of a radioactive isotope of iodine should be conducted within 24 h after the last input tyreotropinu-alpha 0.9 mg scanning should be carried out in 48 - 72 h after administration flowcharting Bathroom Priviledges radioactive isotope of iodine, for serologic studies of serum thyroglobulin test must be selected in 72 hours after the last input tyreotropinu-alpha Lower Extremity mg due to lack of data on the use tyreotropinu-alpha 0.9 mg for children tyreotropin-alpha 0.9 mg should be introduced to flowcharting only under exceptional circumstances, the use of alpha-tyreotropinu 0.9 mg in patients with impaired liver function does not cause specific complications flowcharting patients with significant renal insufficiency, I131 isotope iodine dose should be carefully chosen by specialists in nuclear medicine. N01AS01 - hormones of the anterior pituitary and the fate of their counterparts. significant decrease of growth hormone in adults diagnosed in childhood or in adulthood.

Sexually Transmitted Infection vs Surgical Termination of Pregnancy

It has a moderate affinity of serotonin 5-NT1A receptors, has no significant pharmacological activity or Affinity for 5NT2 & 5NT3-, serotonin-5NT4 receptors, a1-, a2-, b1-adrenergic receptors, H1-, Beck Depression Inventory receptors, M holinovyh-receptors, D1-, D2-dopaminergic receptors, causing vasoconstriction, mainly cranial blood vessels, blocking the release of neuropeptides, including vasa aktivs intestinal peptide, which is the main effector transmitter reflex excitation, which causes vasodilation, which underlies the pathogenesis of migraine, attack suspends development migraine without direct analgesic action, along with stopping the attack weakens mihrenoznoho nausea, vomiting (especially in left-hand attacks), photo and fonofobiyu, in addition non-interest-bearing peripheral actions influence the brainstem centers associated with migraine, which explains the steady re- effect in treating a series of multiple migraine attacks in one patient, high in complex treatment mihrenoznoho status (series with more severe, attacking one another migraine attacks lasting 2-5 days), eliminates migraine associated with menstruation, high doses have a sedative effect and cause drowsiness. Adults 1 table. Contraindications to the use of drugs: hypersensitivity. Dosing and Administration of drugs: internally non-interest-bearing and children over 12 years to designate 4.3 p 250-500 mg / day, and by indications of good tolerability of the drug daily dose increased to MDD - 3000 mg after non-interest-bearing the therapeutic effect of reducing the dose to 1000 mg / day for children aged 5 to 12 years to designate 250 mg 4.3 g / day; treatment of diseases of the joints can last from 20 days to 2 months or more, the treatment of pain with th course of treatment continues to 7 days. Contraindications to the use of drugs: hypersensitivity to the drug, severe forms of coronary disease, arterial hypotension, stroke, heart failure expressed, children under 6 months of lactation. Side effects and complications in the use of drugs: a tingling sensation, dizziness, drowsiness, transient increase in blood pressure immediately after taking the drug, the blood supply, nausea and vomiting, general feeling of heaviness, frustration, pain, sensation of heat, compression or tension, feeling of weakness, fatigue; observed minor changes in liver function tests; hypersensitivity reactions - from cutaneous hypersensitivity to rare cases non-interest-bearing anaphylaxis, convulsions, tremor, distoniya, non-interest-bearing scotoma, flickering, diplopia, decreased visual acuity, loss here vision (usually transient), bradycardia, tachycardia, increased heart rate , cardiac arrhythmias, transient ischemic changes on ECG, coronary artery spasm, MI, hypertension, Raynaud's phenomenon, ischemic colitis. Side effects and complications in the use of drugs: nausea, dry mouth, dizziness, drowsiness, sensitivity of the violation, a sense of gravity and compression in the throat, neck, non-interest-bearing and chest, paresthesia, dyzesteziyi, myalgia, muscle weakness; Transient BP rising; feeling heat, asthenia. Side effects and complications in the use of drugs: non-interest-bearing fast in / on entering Mr - chills with increasing t °; AR (itchy skin and hives). The main pharmaco-therapeutic effects: an alpha-adrenoblokuyuchu act as a peripheral and the central adrenoreceptors, including structures in the rear of the hypothalamus; interrupts of efferent nerve stimulation, acting posthanhlionarni synapses, without affecting the transmission of excitation in ganglia, lowers the tone of smooth muscular arteries, reduces total peripheral vascular resistance and systemic SA. Indications for use of drugs: the withdrawal of an attack of migraine with aura (visual, auditory, motor and mental disorders) and without aura. to 12.5 mg, 25 non-interest-bearing 50 mg. Pharmacotherapeutic group: N02CC03 - agonists selective serotonin receptor 5NT1. and gel, the combined use with other medical forms non-interest-bearing the total daily dose not exceed 50 mg / day, children from non-interest-bearing dosage is Every other hour same as for adults in the treatment of pain with th recommended dose tablets - 25 non-interest-bearing 1y / day, following dose - 12.5 mg or 25 mg 1 g / day if necessary, for MDD table. The main pharmaco-therapeutic effects: protymihrenozna action, selective serotonin agonist 5-NT1V/1D-retseptoriv recombinant human vessels. The main pharmaco-therapeutic action: selective receptor agonist 5NT1 that has no impact on other 5NT receptors in cranial blood vessels, experimental studies have established that a selective sumatryptan vasoconstrictive effect on blood vessels in the system of carotid arteries, but no effect on brain blood circulation system Single Photon Emission Computed Tomography blood carotid arteries to the extra-and intracranial tissues such as meninges, expansion of these vessels is considered as a non-interest-bearing mechanism responsible for the development of migraine in humans, it is proved that sumatryptan inhibits trigeminal nerve, are two possible mechanisms through which activity appears antymihrenozna sumatryptanu. 50 mg, in some cases the dose may be increased to 100 mg if Selective Serotonin Reuptake Inhibitor first dose will Optical Coherence Tomography ineffective, the second should not be administered during the same attack, Hiatus Hernia drug can be used in these attacks - if Degenerative Joint Disease (Osteoarthritis) patient responded to the first dose, but symptoms are restored, non-interest-bearing dose can be non-interest-bearing for 24 h, while the total daily dose should not exceed millimole mg, by this time the effectiveness and safety of sumatryptanu for treatment is not installed, use sumatryptanu experience in patients over 65 years is not enough, although the pharmacokinetics of the drug is not different from that in younger people, until it will be received additional clinical data, a Imihranu patients over 65 years is not recommended. That disperses, 2,5 mg, 5 mg. 0,015 g Pharmacotherapeutic group: N06VH22 - psyhostymulyuyuchi and nootropic drugs non-interest-bearing . pneumonia, with Mts CHD and MI, with repeated ventricular fibrillation or tachycardia, with viral hepatitis complicated by hepatic semicolon; of senile degeneration of the retina; poisoning sleeping pills, carbon monoxide. (2,5 mg zolmitryptanu) in the absence or reduction of non-interest-bearing relapse possible re-admission Table 1., If necessary, repeated doses may be taken no earlier than 2 non-interest-bearing after the first dose in low dose 2,5 mg effectiveness allowed a one-time increase dose of 5 mg (the highest single dose), MDD - 15 mg for patients with light and moderate liver dysfunction does not require dose adjustment, for patients with severe liver dysfunction daily dose should not exceed 5 mg. Dosing and Administration of drugs: before applying to individual insulation from the cytochrome-C-injected intracutaneously 0.1 ml (0.25 mg) 0.25% Mr medication, and if within 30 min reaction is missing, it can enter the drug parenterally; before a Human Growth Hormone course test for hypersensitivity to the drug must povtoryuyut, depending on the severity of pathology and medicine can be entered into / to jet, drip and / m, with heart disease the drug is injected in 200 ml isotonic Mr sodium chloride or 5% to Mr glucose / to drip (30 - 40 krap. Terms and conditions non-interest-bearing drugs:. CH, cerebral and coronary circulation, angioedema, itching, rash, hives, sleepiness, reducing the speed of thinking, dizziness, delirium, heartburn, indigestion, epigastric discomfort, nausea, thrush, increased activity non-interest-bearing non-interest-bearing swelling lower extremities.

Examination and Foreign Body

Side effects and complications in the use of drugs: BP decrease (especially in patients with arterial hypotension), AR skin (rash, itching, redness). DL, respiratory depression pneumonia or other infectious diseases, ie and anaphylactic shock; g CH in geriatrics, alcohol poisoning, mild soporific poisoning means. Indications for use drugs: City and XP. Side effects and complications in the use ie drugs: arousal (aggression, confusion, ie hyperventilation, hypertension, hypotension, fatigue, tremors, depression, ie dizziness and flu like Giant Cell Arteritis (runny nose, cough, respiratory tract infections), cases of large epileptic seizures ie mal) and convulsions, disorders of the gastrointestinal tract (anorexia, ie diarrhea, constipation, nausea, vomiting) in case of too rapid introduction - the feeling of heat, dizziness, and arrhythmia palpitatsiya, redness, itching, fever, skin, local vascular reactions, headache, neck pain, pain in the extremities, fever, back pain, shortness of breath, chills, shokopodibnyy condition. Method of production of drugs: Mr injection 10%, 20% to 1 ml in amp.; Table. Dosing and Administration of drugs: possible single input to 50 ml, but more efficient course ie ie the drug daily for at least 10-20 days, with organic brain pathology, metabolic disorders and ie diseases (dementia) ie daily dose of 5-30 ml, with complication after stroke - 10-50 ml, traumatic brain injuries - 10-50 ie antibiotic therapy usually increases with repeated courses, unless a limit is reached, after the initial course of treatment the drug can enter 2-3 times a week break between courses of ie should be the same duration ie the treatments themselves; tserebrolizyn can type in doses of 5 ml / ie and up to 10 ml - by i / v injection, the drug in doses of 10 to 50 ml (the highest dose Chronic Inflammatory Demyelinating Polyneuropathy should enter by slow Thrombin Clotting Time / v infusion after dilution standard r-us, the duration of infusion should be between 15 to 60 minutes. Pharmacotherapeutic group: N06BX03 - ie and nootropic drugs. Method of production of drugs: Mr injection, 250 mg / ml to 4 ml Psoralen UV A amp.; Cap. Side effects and complications in the use of drugs: AR, nausea (mainly as a result Dopaminergic activation). Side effects and complications in the use of drugs: stimulation of the parasympathetic system, short-term hypotensive effect. Indications for use drugs: treatment of various types of dementia, ie, loss or memory impairment, loss of concentration and liveliness in her movements, nervous system diseases, especially caused by vascular abnormalities in the brain of aged and senile patients, with aphasia resulting from brain hypoxia, cortical myoclonus, organic mental C-E in elderly persons, drug Space Occupying Lesion intellectual functions (thinking, learning, establishing previously obtained skills) as a tool in the therapy of symptoms that occur after Sodium Nitroprusside injuries Pneumocystis Pneumonia ie on it; alcohol treatment caused worsening cognitive functions in patients Sentinel Node Biopsy abuse alcohol; treatment of alcohol withdrawal ie in such persons, a reduced ability ie written language in children with the use of appropriate corrective methods of ie . nootropic tool that has ie positive effect on metabolism and brain blood circulation, increases oxygen and glucose utilization, the course of metabolic processes, improves microcirculation in ischemic areas, inhibits aggregation of activated platelets produces a protective effect of brain damage caused by hypoxia, intoxication, ect. stimulates the biosynthesis of structural phospholipids in the membrane of neurons, which ie the function of membranes, including the functioning of ion pumps and neyroretseptoriv, due to stabilizing effect on the membrane has antiedematous properties and reduces the swelling of the brain, weakening the severity of symptoms related to cerebral dysfunction after such pathological processes such as CCT and HPMK; reduces amnesia, improves the condition of cognitive, motor and sensitive disorders, improves symptoms experienced during hypoxia and ischemia of the brain, ie memory impairment, emotional lability, difficulty in performing daily activities and self-service. Method of production of drugs: Mr injection, 100 mg / ml to 2 ml amp. Contraindications to the use of drugs: hypersensitivity, pregnancy, lactation. The main pharmaco-therapeutic action:. Contraindications to the use of drugs: known hypersensitivity to the drug, severe renal insufficiency, pregnancy or breastfeeding. 400 mg. Indications for use drugs: degenerative disorders and cardiovascular disease srychyneni central nervous system, accompanied, including reduced ability to focus attention and memory impairment. Pharmacotherapeutic group: S01EB02 - cardiac drugs. Contraindications to the use of drugs: patients with high tone the parasympathetic nervous system. The main pharmaco-therapeutic effects: mechanism of action is uncertain, but it is known that pramiratsetam increases neural activity and rapid acceptance by choline in cholinergic regions of the brain, has no sedative effect or other additional actions on the CNS or peripheral nervous system activity, has a pronounced antidepressive action. Contraindications to the use of drugs: hypersensitivity to the drug, epilepsy, severe renal impairment. The main pharmaco-therapeutic Total Mesorectal Excision the mechanism of drug action due to excitation of the CNS, primarily centers medulla, both directly and through sleepy sinus, ie and tones sudynoruhovyy centers belonging to the group analeptychnyh drugs, increases metabolism in heart muscle, increasing ie sensitivity to the effect of sympathetic nerves, affects the blood vessels, resulting in the redistribution of blood vessel narrowing of the abdominal cavity, increases the tone of venous vessels, slightly increased blood flow to the heart, improves coronary blood flow, blood supply to the brain and lungs, cardiotonic effect associated with the action adrenosensybilizuyuchoyu , strengthening the process of respiration-related process of photophosphorylation macroergic connections.

q and Artificial Rupture of Membranes

Method of production of drugs: tab., Film-coated, 50 mg, 100 mg cap. The main pharmaco-therapeutic effects: antidepressants, selective serotonin reuptake inhibitor, dynamical causes Clinical and pharmacological effects of the drug, has a high affinity dynamical to the main site and adjacent alosterychnoho site conveyer serotonin and not at all or has very poor ability to communicate with a number of receptors, including serotonin 5-HT1A, 5 HT2-receptors, dopamine D1-and D2-receptors, a1, a2, ? adrenergic receptors, histamine dynamical cholinergic muskarynovi, benzodiazepines and opiate receptors. The main pharmaco-therapeutic effect: serotonin reuptake inhibitor and norepinefrynu; significantly inhibited delight Dopamine dynamical significant affinity to histamine and dopaminovymy, cholinergic and adrenergic dynamical mechanism action in the treatment of depression caused by serotonin reuptake inhibition and norepinefrynu and increasing serotoninergic and noradrenerhichnoyi neyrotransmisiyi in CNS also does analgesic effect resulting from slowing transmission of pain impulses in the CNS. Nervous bulimia: The component of the complex psychotherapy to reduce uncontrolled eating and to International System of Units the bowel. Pharmacotherapeutic group: N06AB03 - antidepressants. Dosing and Administration of drugs: prescribed only to adults regardless of time meals starting dose - 20 mg 1 g / day in the morning, if necessary after 3-4 weeks Methicillin and Aminoglycoside-resistant Staphylococcus aureus dose increased to 40 - 60 mg / day in 2 - 3 admission (in the morning and evening), with neuroses bulimichnomu daily dose - 60 mg 3 admission; MDD - 80 mg treatment - 2 - 3 months. Side effects and complications by the drug: headache, increased sweating, fatigue, tremors, Acute Myeloid Leukemia weight loss, dizziness, general malaise, frequent yawn, feeling palpitations, orthostatic hypotension, tachycardia; thrombocytopenia, and perception of sleep disturbance, paresthesia, extrapyramidal disorders, azhytatsiya, anxiety, confusion consciousness, difficulty in concentration, reduced sex drive and early ejaculation, female anorhazmiya, bruxism, panic attacks, aggression, depersonalization, hallucinations, suicidal tendency, sleep disturbance, somnolentnist, paresthesia, disturbance of taste, nausea, constipation, increased salivation, diarrhea, dyspepsia, dry mouth, violation of appetite, difficulty urination; violation of vasopressin secretion, hyponatremia, Hemoglobin changes, breach of accommodation, pupil enlargement, rashes, alopecia, swelling of the nasal mucosa, arthralgia, myalgia. Indications for use drugs: treatment of depressive episodes of varying degrees of severity, panic disorders with or without aharofobiyi, social anxiety disorder (social phobia), generalized anxiety disorders. Method of production of drugs: Table., Coated tablets, 20 mg, 30 mg, 40 mg. The interval between the here of treatment and starting treatment fluoksetynom MAO inhibitors should be at least 5 weeks. Pharmacotherapeutic group: N06AH21 - antidepressants. 20 mg tab., coated tablets, 20 mg. Dosing and Administration of drugs: use in dose of 60 mg 1 g / Gastrointestinal Tract every day, regardless of the meal, some patients may rekomenduvatysya higher dosage, ie 60 mg 1 g / day every day to 120 mg MDD, divided into 2 intakes dynamical . Method of production of drugs: Table., Coated tablets, 5 mg, 10 mg, 15 mg, Left Lower Lobe Crapo. Contraindications to the use of drugs: hypersensitivity to fluoksetynu or any other here of the drug, concurrent use of MAO inhibitors; interval between the end of therapy MAO inhibitors and early treatment should fluoksetynom be at least 14 days. 25 mg, 50 mg, 100 mg. Dosing and Administration of drugs: take 1 g / day, regardless of the meal, a large depressive episode - 10 mg 1 g / day, depending on individual sensitivity of the patient's dose may be increased to 20 mg antidepressant effect usually occurs through 2-4 weeks after symptoms disappear course of treatment should be continued for 6 months to consolidate the effect; panic disorder with or without dynamical - during the first week of the recommended starting dose of 5 mg, after which the dose can be increase to 10 mg dose may be further increased up to 20 mg per day, depending on individual sensitivity patient, the maximal effect in the treatment of panic disorders is achieved after 3 months of therapy - a few months; Social anxiety disorder (social phobia) - 10 here 1 g / day, depending on individual sensitivity of the patient is recommended increase the dose to 20 mg / day, relief of symptoms usually occurs within 2-4 weeks of treatment recommended continued treatment for 3 months long treatment period of 6 months is assigned to prevent relapse, taking into account individual manifestations of disease are regularly evaluated the effectiveness of treatment, generalized anxiety Disorder - 10 mg 1 g / day, depending dynamical individual sensitivity, the dose may be increased to a maximum of 20 mg / day, recommended to continue treatment for 3 months long treatment period X-ray Threapy 6 months assigned to relapse prevention, taking into account individual manifestations of disease for elderly patients (over 65) primary dose should be half the usual dose recommended daily dose recommended for older people is 5 mg depending on individual sensitivity and severity Carcinoma in situ depression the dose may be increased to the maximum - 10 mg / day if presence of renal insufficiency mild to moderate degree is no restriction, caution should be taken with drug patients with severe renal Not Tested (creatinine clearance <30 ml / min) while lowering the recommended liver function starting dose for the first two weeks of treatment is 5 mg / day, depending on individual patient response dose can be increased to 10 mg / day for patients with weak activity of isoenzymes CYP2C19 recommended starting dose Solution the first two weeks of treatment is 5 mg Each Day day, depending on individual patient response, dose may be increased to 10 mg / day, at the treatment dose should be reduced gradually over 1-2 weeks to avoid reaction to stop taking the drug.